Risk of neuroinflammatory diseases among new users of biologic and targeted synthetic disease-modifying antirheumatic drugs.

The overall risk of neuroinflammatory events among new users of TNF inhibitors did not differ substantially as compared to new users of other b/tsDMARDs. Meta-analyses of randomized trials should be conducted to corroborate these findings, which may be affected by channeling bias.